Keyphrases
Thrombotic Thrombocytopenic Purpura
98%
Venous Thromboembolic Disease
66%
Single Center
66%
Venous Thromboembolism
65%
Bleeding
56%
Thrombosis
49%
Thrombotic Microangiopathy
40%
Hemophilia
38%
Clopidogrel
37%
Patients with Cancer
36%
Cancer-related
34%
Pharmacovigilance
33%
Clinical Practice Guidelines
33%
Oncology
33%
Cancer Patients
33%
NCCN Guidelines
33%
Ticlopidine
32%
Risk Factors
30%
Adult Patients
28%
Acquired Hemophilia A
27%
Hemophilia Patients
25%
Von Willebrand Factor
25%
Bleeding Complications
24%
Thienopyridines
24%
Hairy Cell Leukemia
23%
Purine Analogues
23%
Atypical Hemolytic Uremic Syndrome (aHUS)
22%
Drug Dependence
21%
Myeloproliferative Neoplasms
20%
Von Willebrand Disease
20%
Adverse Effects
17%
ADAMTS13
17%
Therapeutic Plasma Exchange
17%
High Risk
16%
Drug-induced Thrombotic Microangiopathy
16%
Splenectomy
16%
Congenital Dyserythropoietic Anemia
16%
Thrombosis Treatment
16%
Factor IXa
16%
Clinical Outcomes
16%
BCR-ABL Negative
16%
Brain Tumor
16%
Hemostatic Function
16%
High-grade Glioma
16%
Caplacizumab
16%
Placental Transfer
16%
Human Tissue
16%
Pharmaceutical Wholesaler
16%
Bleeding Disorders
16%
Cyclosporine
16%
Medicine and Dentistry
Venous Thromboembolism
100%
Bleeding
80%
Malignant Neoplasm
73%
Diseases
56%
Thrombotic Thrombocytopenic Purpura
51%
Thrombosis
51%
Microangiopathy
41%
Haemophilia A
41%
Oncology
33%
Blood Clotting Factor 8
28%
Hemostat
22%
Myeloproliferative Neoplasm
20%
Adverse Event
20%
Von Willebrand Disease
19%
Hairy Cell Leukemia
16%
Purine
16%
Von Willebrand Factor
16%
Thromboplastin
16%
Ferric Carboxymaltose
16%
Placental Transfer
16%
Human Tissue
16%
Congenital Dyserythropoietic Anemia Type II
16%
Tumor Progression
16%
Iron Deficiency
16%
Polycythemia vera
16%
Tumor Angiogenesis
16%
Observational Study
16%
Caplacizumab
16%
Vasculotropin
16%
Autoantibodies
16%
Tumor Model
16%
Atypical Hemolytic Uremic Syndrome
16%
Hematologic Malignancy
16%
Angiogenesis Inhibitor
16%
Factor IX
16%
Prevalence
16%
Ganglioglioma
16%
Liver Transplantation
16%
Bevacizumab
16%
Pancreas Cancer
16%
Leukemia Survival
16%
Von Willebrand Factor Cleaving Proteinase
16%
Intracranial Tumor
16%
Bone Remodeling
16%
Odds Ratio
16%
Infusion
14%
Fibroblast Growth Factor 23
11%
Vatalanib
11%
Asparaginase
11%
Janus Kinase
11%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
100%
Thrombotic Thrombocytopenic Purpura
66%
Malignant Neoplasm
61%
Disease
48%
Clopidogrel
39%
Pharmacovigilance
33%
Purine Derivative
33%
Hairy Cell Leukemia
33%
Purine
33%
Thrombosis
27%
Remission
25%
Haemophilia A
25%
Ticlopidine
24%
Thienopyridine
24%
Adverse Event
17%
Glioma
16%
Caplacizumab
16%
Ferric Carboxymaltose
16%
Blood Clotting Factor 8
16%
Hemostatic Agent
16%
Hematologic Malignancy
16%
Observational Study
16%
Angiogenesis Inhibitor
16%
Iron Deficiency
16%
Vasculotropin
16%
Pentostatin
16%
Bevacizumab
16%
Blood Clotting Factor 9
16%
Intracranial Tumor
16%
Bleeding
13%
Fibroblast Growth Factor 23
11%
Vatalanib
11%
Asparaginase
11%
Thalidomide
11%
Rituximab
10%
Deep Vein Thrombosis
8%
Interferon
8%
Recurrence Risk
8%
Haemophilia B
8%
Cladribine
8%
Bleeding Disorder
8%
Splenomegaly
8%
Pseudomonas Exotoxin
8%
Overall Survival
8%
Neoplasm
8%
Cytopenia
8%
Blood Clotting Factor 9 Concentrate
8%
Replacement Therapy
8%
Pharmacokinetics
8%
Anticoagulant Agent
7%